Zeinalian Mehrdad, Hadian Mahdi, Hashemzadeh-Chaleshtori Morteza, Salehi Rasoul, Emami Mohammad Hassan
Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Int J Hematol Oncol Stem Cell Res. 2017 Jul 1;11(3):240-245.
Familial colorectal cancer type X (FCCX) is a subtype of mismatch repair (MMR)-proficient colorectal cancerin which the patients are clinically at risk for Lynch syndrome (LS), a common hereditary cancer predisposing syndrome. In this study, we described a new clinicopathological feature of the condition in central Iran. We designed a descriptive, retrospective study to screenat-risk colorectal cancer (CRC) patients, using Amsterdam II criteria and Molecular analysis in Isfahan (central Iran) throughout 2000-2013 period. 219 early-onset (≤ 50 years) CRC patients of 1659 were selected for the evaluation. Amsterdam II criteria were positive in 45 families; of whom 31 were finally analyzed by molecular testing. MMR deficiency was detected in 7/31 probands (22.6%) as affected to LS, so 24 families (77.4%) were identified as FCCX. The mean age of the probands at diagnosis among FCCX families was 45.3 years (range 24-69) versus 38.0 years (range 31-50) in LS families. The frequency of CRC among FCCX and LS families was calculated 27.9% and 67.5%, respectively. Also, the most frequent extracolonic cancer among both FCCX and LS families was stomach by 25.5% and 30.8%, respectively. Tumor site was proximal to the splenic flexure in 20.8% and 57.1% of index CRC patients in FCCX and LS families, respectively. Given the relative high frequency of FCCX and its different phenotype among Iranian populations, we need to set up more advanced molecular studies for exploration of unknown molecular pathways leading to tumorigenesis in this class of CRC patients.
X型家族性结直肠癌(FCCX)是错配修复(MMR)功能正常的结直肠癌的一种亚型,这类患者临床上有患林奇综合征(LS)的风险,林奇综合征是一种常见的遗传性癌症易感综合征。在本研究中,我们描述了伊朗中部地区该病的一种新的临床病理特征。我们设计了一项描述性回顾性研究,在2000年至2013年期间,使用阿姆斯特丹Ⅱ标准和分子分析方法,对伊朗中部伊斯法罕有风险的结直肠癌(CRC)患者进行筛查。从1659例患者中选取219例早发型(≤50岁)CRC患者进行评估。45个家族符合阿姆斯特丹Ⅱ标准;其中31个最终通过分子检测进行分析。在31名先证者中有7名(22.6%)检测到MMR缺陷,诊断为患LS,因此24个家族(77.4%)被确定为FCCX。FCCX家族中先证者诊断时的平均年龄为45.3岁(范围24 - 69岁),而LS家族中为38.0岁(范围31 - 50岁)。FCCX家族和LS家族中CRC的发生率分别计算为27.9%和67.5%。此外,FCCX家族和LS家族中最常见的结外癌症均为胃癌,分别为25.5%和30.8%。FCCX家族和LS家族中,分别有20.8%和57.1%的首发CRC患者肿瘤部位在脾曲近端。鉴于FCCX在伊朗人群中的相对高发生率及其不同的表型,我们需要开展更先进的分子研究,以探索导致这类CRC患者肿瘤发生的未知分子途径。